Alzheimer's Disease Neuroimaging Initiative 3 (ADNI 3)

ADNI 3Courtesy of the USC Laboratory of Neuro Imaging and Athinoula A. Martinos Center for Biomedical Imaging,
Consortium of the Human Connectome Project.

The Alzheimer’s Disease Neuroimaging Initiative (ADNI), is a landmark partnership and study that for 12 years has profoundly influenced our understanding of Alzheimer’s disease by identifying the earliest changes in brain structure and function that signal its onset and progression. The study is led by the National Institute on Aging with support from the FNIH and more than 30 organizations since its launch in 2004.

The third phase of ADNI launched in September 2016, building on the success of previous phases with new additions, including:

  • Recruiting 1,200 volunteers to join about 800 current participants to enrich the existing dataset;
  • Using state-of-the-art PET imaging techniques to monitor brain levels of tau, a protein that is often abnormal in Alzheimer’s patients;
  • Performing cutting-edge systems biology analyses to holistically assess complex interactions between the brain and body;
  • Assessing cognitive function through computer tests at home and in the doctor’s office and measure changes in subjects’ ability to handle money, which can be a warning sign of the disease.

ADNI 3 will run until July 31, 2021.


The FNIH is currently seeking funding commitments to support this program. For more information, please contact

ADNI 3 Partners